Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Strata Critical Medical, Inc.BLDE · Entity 5512 | Chief Technology Officer | November 09, 2022 | November 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Strata Critical Medical, Inc.
Report date November 09, 2022 · Filed November 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 111,754 |
Reported balance
After 2022-11-09 transaction · row 1
1 source rowRow 1 · 2022-11-09 · Grant · Acquired 68,737 · Balance 111,754 F1: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 6.25% (rounded down to the nearest whole number) will vest on the first day of every calendar quarter following January 1, 2023 (with the first tranche to vest on April 1, 2023), with any remaining unvested RSUs to vest on January 1, 2027, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 6.25% (rounded down to the nearest whole number) will vest on the first day of every calendar quarter following January 1, 2023 (with the first tranche to vest on April 1, 2023), with any remaining unvested RSUs to vest on January 1, 2027, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2022 Filed Nov 14, 2022 10:02 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 68,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-22-000118 · wf-form4_166843807685193.xml · nonDerivative · entry 1 Arkhipenko Anatoli · CIK 0001924934 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,754 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 6.25% (rounded down to the nearest whole number) will vest on the first day of every calendar quarter following January 1, 2023 (with the first tranche to vest on April 1, 2023), with any remaining unvested RSUs to vest on January 1, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 05, 2022 Filed Jun 3, 2022 16:01 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 43,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001924934-22-000004 · primary_doc.xml · nonDerivative · entry 1 Arkhipenko Anatoli · CIK 0001924934 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,017 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. The RSUs will vest over 48 months, with 25% (rounded down to the nearest whole number) vesting on April 11, 2023, and 6.25% (rounded down to the nearest whole number) vesting every three months following April 11, 2023, with any remainder to vest on April 11, 2026, such that 100% will be vested on April 11, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.